Literature DB >> 10191269

Roles of key active-site residues in flavocytochrome P450 BM3.

M A Noble1, C S Miles, S K Chapman, D A Lysek, A C MacKay, G A Reid, R P Hanzlik, A W Munro.   

Abstract

The effects of mutation of key active-site residues (Arg-47, Tyr-51, Phe-42 and Phe-87) in Bacillus megaterium flavocytochrome P450 BM3 were investigated. Kinetic studies on the oxidation of laurate and arachidonate showed that the side chain of Arg-47 contributes more significantly to stabilization of the fatty acid carboxylate than does that of Tyr-51 (kinetic parameters for oxidation of laurate: R47A mutant, Km 859 microM, kcat 3960 min-1; Y51F mutant, Km 432 microM, kcat 6140 min-1; wild-type, Km 288 microM, kcat 5140 min-1). A slightly increased kcat for the Y51F-catalysed oxidation of laurate is probably due to decreased activation energy (DeltaG) resulting from a smaller DeltaG of substrate binding. The side chain of Phe-42 acts as a phenyl 'cap' over the mouth of the substrate-binding channel. With mutant F42A, Km is massively increased and kcat is decreased for oxidation of both laurate (Km 2. 08 mM, kcat 2450 min-1) and arachidonate (Km 34.9 microM, kcat 14620 min-1; compared with values of 4.7 microM and 17100 min-1 respectively for wild-type). Amino acid Phe-87 is critical for efficient catalysis. Mutants F87G and F87Y not only exhibit increased Km and decreased kcat values for fatty acid oxidation, but also undergo an irreversible conversion process from a 'fast' to a 'slow' rate of substrate turnover [for F87G (F87Y)-catalysed laurate oxidation: kcat 'fast', 760 (1620) min-1; kcat 'slow', 48.0 (44.6) min-1; kconv (rate of conversion from fast to slow form), 4.9 (23.8) min-1]. All mutants showed less than 10% uncoupling of NADPH oxidation from fatty acid oxidation. The rate of FMN-to-haem electron transfer was shown to become rate-limiting in all mutants analysed. For wild-type P450 BM3, the rate of FMN-to-haem electron transfer (8340 min-1) is twice the steady-state rate of oxidation (4100 min-1), indicating that other steps contribute to rate limitation. Active-site structures of the mutants were probed with the inhibitors 12-(imidazolyl)dodecanoic acid and 1-phenylimidazole. Mutant F87G binds 1-phenylimidazole >10-fold more tightly than does the wild-type, whereas mutant Y51F binds the haem-co-ordinating fatty acid analogue 12-(imidazolyl)dodecanoic acid >30-fold more tightly than wild-type.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10191269      PMCID: PMC1220167     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  42 in total

1.  Domains of the catalytically self-sufficient cytochrome P-450 BM-3. Genetic construction, overexpression, purification and spectroscopic characterization.

Authors:  J S Miles; A W Munro; B N Rospendowski; W E Smith; J McKnight; A J Thomson
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

2.  Decreased substrate affinity upon alteration of the substrate-docking region in cytochrome P450(BM-3).

Authors:  S A Maves; H Yeom; M A McLean; S G Sligar
Journal:  FEBS Lett       Date:  1997-09-08       Impact factor: 4.124

3.  The structure of the cytochrome p450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid.

Authors:  H Li; T L Poulos
Journal:  Nat Struct Biol       Date:  1997-02

4.  A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate and the regiospecificity of hydroxylation.

Authors:  C F Oliver; S Modi; M J Sutcliffe; W U Primrose; L Y Lian; G C Roberts
Journal:  Biochemistry       Date:  1997-02-18       Impact factor: 3.162

5.  The catalytic mechanism of cytochrome P450 BM3 involves a 6 A movement of the bound substrate on reduction.

Authors:  S Modi; M J Sutcliffe; W U Primrose; L Y Lian; G C Roberts
Journal:  Nat Struct Biol       Date:  1996-05

6.  Probing electron transfer in flavocytochrome P-450 BM3 and its component domains.

Authors:  A W Munro; S Daff; J R Coggins; J G Lindsay; S K Chapman
Journal:  Eur J Biochem       Date:  1996-07-15

7.  Heme-coordinating analogs of lauric acid as inhibitors of fatty acid omega-hydroxylation.

Authors:  P Lu; M A Alterman; C S Chaurasia; R B Bambal; R P Hanzlik
Journal:  Arch Biochem Biophys       Date:  1997-01-01       Impact factor: 4.013

8.  An active site substitution, F87V, converts cytochrome P450 BM-3 into a regio- and stereoselective (14S,15R)-arachidonic acid epoxygenase.

Authors:  S Graham-Lorence; G Truan; J A Peterson; J R Falck; S Wei; C Helvig; J H Capdevila
Journal:  J Biol Chem       Date:  1997-01-10       Impact factor: 5.157

Review 9.  Bacterial cytochromes P-450.

Authors:  A W Munro; J G Lindsay
Journal:  Mol Microbiol       Date:  1996-06       Impact factor: 3.501

10.  Analysis of the structural stability of the multidomain enzyme flavocytochrome P-450 BM3.

Authors:  A W Munro; J G Lindsay; J R Coggins; S M Kelly; N C Price
Journal:  Biochim Biophys Acta       Date:  1996-09-05
View more
  53 in total

1.  Comparison of the dynamics of substrate access channels in three cytochrome P450s reveals different opening mechanisms and a novel functional role for a buried arginine.

Authors:  Peter J Winn; Susanna K Lüdemann; Ralph Gauges; Valère Lounnas; Rebecca C Wade
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

2.  Functional characterisation of an engineered multidomain human P450 2E1 by molecular Lego.

Authors:  Michael Fairhead; Silva Giannini; Elizabeth M J Gillam; Gianfranco Gilardi
Journal:  J Biol Inorg Chem       Date:  2005-11-09       Impact factor: 3.358

3.  Evolutionary history of a specialized p450 propane monooxygenase.

Authors:  Rudi Fasan; Yergalem T Meharenna; Christopher D Snow; Thomas L Poulos; Frances H Arnold
Journal:  J Mol Biol       Date:  2008-06-28       Impact factor: 5.469

4.  Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.

Authors:  Rüdiger Kaspera; Suresh B Naraharisetti; Eric A Evangelista; Kristin D Marciante; Bruce M Psaty; Rheem A Totah
Journal:  Biochem Pharmacol       Date:  2011-06-24       Impact factor: 5.858

Review 5.  Microbial cytochromes P450: biodiversity and biotechnology. Where do cytochromes P450 come from, what do they do and what can they do for us?

Authors:  Steven L Kelly; Diane E Kelly
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-06       Impact factor: 6.237

6.  Role of residue 87 in substrate selectivity and regioselectivity of drug-metabolizing cytochrome P450 CYP102A1 M11.

Authors:  Eduardo Vottero; Vanina Rea; Jeroen Lastdrager; Maarten Honing; Nico P E Vermeulen; Jan N M Commandeur
Journal:  J Biol Inorg Chem       Date:  2011-05-13       Impact factor: 3.358

Review 7.  Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development.

Authors:  Chris J Paddon; Jay D Keasling
Journal:  Nat Rev Microbiol       Date:  2014-04-01       Impact factor: 60.633

Review 8.  Design and engineering of artificial oxygen-activating metalloenzymes.

Authors:  Flavia Nastri; Marco Chino; Ornella Maglio; Ambika Bhagi-Damodaran; Yi Lu; Angela Lombardi
Journal:  Chem Soc Rev       Date:  2016-06-24       Impact factor: 54.564

9.  Expression, purification and characterization of cytochrome P450 Biol: a novel P450 involved in biotin synthesis in Bacillus subtilis.

Authors:  A J Green; S L Rivers; M Cheeseman; G A Reid; L G Quaroni; I D Macdonald; S K Chapman; A W Munro
Journal:  J Biol Inorg Chem       Date:  2001-06       Impact factor: 3.358

10.  An efficient light-driven P450 BM3 biocatalyst.

Authors:  Ngoc-Han Tran; Daniel Nguyen; Sudharsan Dwaraknath; Sruthi Mahadevan; Garrett Chavez; Angelina Nguyen; Thanh Dao; Sarah Mullen; Thien-Anh Nguyen; Lionel E Cheruzel
Journal:  J Am Chem Soc       Date:  2013-09-19       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.